Acapodene

This page contains recent news articles, when available, and an overview of Acapodene but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Investor profits as GTx still in the red  -  Apr 8, 2008
And it plans this year to file an FDA new drug application for the use of its drug Acapodene against symptoms related to androgen deprivation therapy, commercialappeal.com (subscription),

GTx, Inc.: A Diamond in a Mud Pit  -  Apr 2, 2008
One of the company’s most promising late-stage medicines is toremifene citrate, or Acapodene. It is used to help treat patients with advanced prostate Seeking Alpha,

GTX initiated with "market outperform"  -  Mar 25, 2008
In a research note published this morning, the analysts mention that the company is currently developing Acapodene in a pivotal Phase III clinical trial for newratings.com,

Analyst initiations: PCLN, GTXI, AKNS and NEXM  -  Mar 25, 2008
Rodman & Renshaw is positive on GTX Inc's (NASDAQ: GTXI) opportunity for Acapodene in prostate cancer and Ostarine for muscle wasting. BloggingStocks

GTX Shares Rise on Analyst Outlook  -  Mar 25, 2008
He said the company's developing drug Acapodene could have potential for multiple uses on the market. The drug is being studied as a treatment for side Houston Chronicle,

GTx Announces Upcoming Presentation of Toremifene Citrate 80 mg ...  -  Apr 8, 2008
GTx is developing ACAPODENE® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, Business Wire (press release),

GTx Announces Webcast of Corporate Presentation at the 28 th ...  -  10 Mar 2008
The GTx presentation, which will highlight the company’s clinical development programs and the recently announced results of the ACAPODENE® 80 mg Phase III Business Wire (press release),

Toremifene (Acapodene) Reduces Fracture Risk from Androgen ...  -  Feb 27, 2008
GTx here said toremifene (Acapodene), a selective estrogen receptor modulator, also had a favorable impact on bone mineral density, lipids, and androgen MedPage Today,

GTx reports promising results for Acapodene drug  -  Feb 25, 2008
The company reported that an 80 milligram dose of the drug Acapodene caused a significant reduction in side effects for men undergoing a treatment for commercialappeal.com (subscription),

GTx: Androgen therapy drug test positive  -  Mar 3, 2008
New Phase III data from tests of GTx Inc.'s Acapodene show that the 80 milligram dose of the drug reduces hot flashes in men with prostate cancer on Bizjournals.com,

UPDATE: GTx Drug Cuts Side Effects In Cancer Therapy  -  Feb 25, 2008
In the study, Acapodene met its main goal of reducing osteoporosis-related vertebral fractures, a possible side effect of hormone therapy. CNNMoney.com

GTx Surges on Late-Stage Trial Results  -  Feb 25, 2008
Shares of GTxGTXI soared nearly 50% Monday after the biopharmaceutical company said its Acapodene drug showed success in a late-stage study in reducing side TheStreet.com

GTx: A Compelling Biotech  -  Feb 11, 2008
The company expects data from two phase III studies for its lead drug candidate, Acapodene, during the first quarter of 2008. BusinessWeek

GTx drug cuts hot flashes  -  Mar 3, 2008
By Daniel Connolly Memphis pharmaceutical company GTx Inc. said Monday that its experimental drug Acapodene reduces hot flashes in men who are undergoing a commercialappeal.com (subscription),

New drug's results 'exciting' for GTx  -  Feb 25, 2008
The successful testing of the pharmaceutical company's new drug -- Acapodene -- also boosts Memphis' effort to make biotechnology a cornerstone of economic commercialappeal.com (subscription),

GTx Drug Gives Men Pause  -  Feb 25, 2008
The new drug will be called Acapodene. "This is very big for us. We've been on this trail for ten years, so to have a positive phase three is pretty Forbes,

GTx shares up 40% on late-stage trial  -  Feb 25, 2008
GTx Inc. plans to file a New Drug Application with the Food and Drug Administration, after releasing key data about its 80 milligram dosage of Acapodene. Bizjournals.com,

S&P Picks and Pans: EA, Take-Two  -  Feb 25, 2008
...-S.Silver The shares are up sharply this morning as GTXI announces positive Phase III results for lead candidate Acapodene for treating side effects of BusinessWeek

GTx loss widens in 4Q  -  Feb 19, 2008
..."We continued to execute on our business plan in 2007 by advancing Acapodene and forging an important strategic SARM (selective androgen receptor modulator) Bizjournals.com,

Ipsen says toremifene citrate meets targets in phase 3 trial  -  Feb 25, 2008
25, 2008 (Thomson Financial delivered by Newstex) -- Ipsen said Acapodene, or toremifene citrate, has met primary and key secondary endpoints in a phase III CNNMoney.com

Ageless Makes Testosterone Treatments Affordable  -  Mar 3, 2008
Acapodene and Ostarine are being developed to counter the harshest side effects of chemotherapy by stimulating bone mass, muscle mass and appetite. Memphis Daily News,

S&P analyst touts GTx products  -  Feb 12, 2008
Acapodene represents "a significant opportunity" in the treatment and prevention of prostate cancer and each dosage (20 and 80 milligrams) has greater than Bizjournals.com,

Q4 2007 Earnings Call  -  Feb 19, 2008
As we have stated previously, we anticipate releasing top line results of our ACAPODENE 80mg Phase III ADT clinical trial and conducting the efficacy Seeking Alpha,

GTX Inc. 4Q loss widens, revenue declines  -  Feb 19, 2008
The Memphis, Tenn. biopharmaceutical company said expects releasing top line results of the Acapodene 80 milligram Phase III ADT clinical trial by the end Forbes,

GTx Phase 3: A Win for Prostate Cancer Sufferers and for ...  -  Feb 27, 2008
A few years back, as a consultant, I was asked by GTX (GTXI) to take a look at their unreleased Phase 2 ACAPODENE (toremifene citrate 80 mg) data and to Seeking Alpha,

Pharma Sector: Few Newsmakers Of The Week - Wyeth, GTx, Allergan ...  -  Mar 8, 2008
The drug, which would be marketed under the brand name Acapodene, is in the same class as AstraZeneca's breast cancer drug tamoxifen and Eli Lilly's Evista, RTT News,

Jacobs Engg. Receives District Of Columbia Consolidated Forensics ...  -  Feb 19, 2008
Mitchell Steiner, Chief Executive Officer of GTx, stated, “We are now focused on obtaining the top line results of the ACAPODENE 80 mg Phase III ADT RTT News,

GTx Good News on ADT Gives its Stock a 36 Percent Boost  -  Feb 25, 2008
GTx Inc. said results from a Phase III study of its investigational drug Acapodene (toremifene citrate, 80 mg), showed that it works to reduce spinal Therapeutics Daily (subscription) (press release),

Ipsen's Full Year 2007 Results and Financial Objectives for the ...  -  Feb 27, 2008
...such as the phase III for Acapodene(R), phase II for our GLP-1 analogue partnered with Roche or phase I for our promising anti-tumor agent STX-64, FOXBusiness

GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in ...  -  Feb 26, 2008
GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, FOXBusiness

Ipsen: Toremifene Citrate 80 mg Meets Primary and Key Secondary ...  -  Feb 26, 2008
Ipsen (Paris:IPN) announced today that GTx Inc. (NASDAQ: GTXI), from which it licensed the European rights for Acapodene(R) (toremifene citrate 80 mg) in FOXBusiness

Winners & Losers Monday's Health Winners & Losers  -  Feb 25, 2008
Also on the rise was GTxGTXI, which soared 39% to $18 after the company said its Acapodene drug was successful in reducing side effects of prostate cancer TheStreet.com

GTx Announces Additional Top Line Phase III Data Demonstrating ...  -  Mar 3, 2008
GTx is developing ACAPODENE ® (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, Business Wire (press release),

Ipsen lays out plans for another successful year in 2008  -  Feb 28, 2008
He added that the recent publication of clinical results, such as the impressive Phase III data for the prostate cancer drug Acapodene (toremifene), Pharma Times (subscription),

Results in line with the Group’s objectives  -  Feb 26, 2008
...such as the phase III for Acapodene ® , phase II for our GLP-1 analogue partnered with Roche or phase I for our promising anti-tumor agent STX-64, Business Wire (press release),

GTx and Ipsen cheered by Phase III data on toremifene  -  Feb 26, 2008
Stephane Thiroloix, executive vice president of corporate development at the French drugmaker, said that the drug, which Ipsen will sell as Acapodene, Pharma Times (subscription),

Phase III Clinical Trial in Advanced Prostate Cancer Patients on ...  -  Feb 25, 2008
Ipsen (Paris:IPN) announced today that GTx Inc. (NASDAQ: GTXI), from which it licensed the European rights for Acapodene^® (toremifene citrate 80 mg) in Vereinigte Wirtschaftsdienste,

Downtown gains needed tenant  -  Jan 24, 2008
French pharmaceutical company Ipsen signed a multimillion-dollar deal with GTx in September 2006 to develop and market Acapodene throughout most of Europe commercialappeal.com (subscription),

S&P Equity Research Upgrades GTX Corp (GTXI) to Strong Buy  -  Jan 28, 2008
S&P analyst, S. Silver, says, "The upgrade reflects our view that development risks for Acapodene are being too heavily discounted, given prior interim data StreetInsider.com (subscription),

Zacks.com announces that Nadine Wong highlights: Pfizer and gtx  -  Nov 12, 2007
Acapodene is a selective estrogen receptor modulator (SERM) that is the subject of two pivotal Phase III trials being conducted under spas, PR-Inside.com (Pressemitteilung),

gtx, Inc. Reports Third Quarter 2007 Financial Results  -  Nov 6, 2007
Later this quarter the last patient will complete the Phase III ACAPODENE ADT clinical trial, and in the Phase III ACAPODENE high grade PIN clinical trial, Business Wire (press release),

gtx, Merck in $500M Deal For Muscle Loss Drugs  -  Nov 6, 2007
...gtx's lead SERM product Acapodene (toremifene citrate) is being tested to treat serious adverse effects related to androgen deprivation therapy for advanced BioWorld Online,

gtx "buy," target price raised  -  Nov 7, 2007
The company is likely to achieve Acapodene sales of $64 million and $158 million in 2009 and 2010, respectively, Lazard Capital adds. newratings.com,

wallstreetstockreview.com: Stocks to Watch: (OTCBB: GXPI), (Nasdaq ...  -  Nov 8, 2007
...gtx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE. gtx has executed an agreement for a collaboration with Trading Markets (press release),

gtx, Inc. and Merck & Co., Inc. Enter Global Strategic ...  -  Nov 6, 2007
...gtx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE. gtx has agreed to a collaboration with Merck & Co., Business Wire (press release),

Merck flexes muscle with gtx deal  -  Nov 7, 2007
...trials under the name Acapodene for the prevention of prostate cancer and as a therapy to ameliorate the side effects of androgen deprivation therapy. OutSourcing-Pharma.com,

gtx of Memphis teams with Merck to fight muscle, bone loss in elderly  -  Nov 6, 2007
It is currently testing two varieties of Acapodene, an experimental prostate cancer drug. Last year it signed a deal with French pharmaceutical firm Ipsen commercialappeal.com (subscription),

GTx to Present at the UBS Global Life Sciences Conference  -  Sep 18, 2007
GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE. GTx also is developing Ostarine(TM), a first-in-class PharmaLive.com (press release),

GTx Announces Webcast of Corporate Presentation at the BioCentury ...  -  Aug 30, 2007
GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE. GTx also is developing Ostarine™, a first-in-class Business Wire (press release),

GTx's Phase III Clinical Development of Acapodene on Course ...  -  Jul 12, 2007
PharmaLive.com (press release),..."The DSMB reviewed safety data of the approximately 3000 patients enrolled in the two pivotal Phase III ACAPODENE clinical trials and recommended that GTx

GTx's prostate cancer drug moving forward  -  Jul 12, 2007
Bizjournals.com,Memphis drug developer GTx Inc. will go forward in the third phase of clinical trials of Acapodene, a treatment for prostate cancer and the side effects of

GTx "buy"  -  Jun 26, 2007
newratings.comIn a research note published this morning, the analysts mention that the LCM survey indicates that Acapodene has the potential to generate significant sales

GTx Announces Webcast of Corporate Presentation at Goldman Sachs ...  -  Jun 5, 2007
Business Wire (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing Ostarine™, a first-in-class

GTx Announces Presentation of Ostarine™ and ACAPODENE® Data at ...  -  25 May 2007
Business Wire (press release),...the ongoing Phase III clinical trial evaluating ACAPODENE® (toremifene citrate) 80 mg for the treatment of multiple side effects of androgen deprivation

Monday's Small-Cap Winners & Losers  -  Apr 30, 2007
TheStreet.comIn the case of GTX, a Leerink Swann & Co. analyst said flaws in an advanced-phase study of the biotech's prostate-cancer treatment, Acapodene,

GTx on brink of major drug breakthroughs  -  May 2, 2007
commercialappeal.com (subscription),It plans to bring two versions of its anti-prostate cancer drug Acapodene to the Food and Drug Administration in 2008 and 2009, and two versions of its

Research and Markets: New Cancer Drug Tracker Acapodene Report ...  -  Apr 17, 2007
Business Wire (press release),...and Markets (http://www.researchandmarkets.com/reports/c54270) has announced the addition of “New Cancer Drug Tracker: Acapodene�? to their offering.

GTx to Host an Analyst Day to Provide an Update on Acapodene Phase ...  -  Apr 11, 2007
PharmaLive.com (press release),Dr. Matthew Smith, Associate Professor of Medicine at Harvard Medical School, the Lead Principal Investigator for the Phase III clinical trial of ACAPODENE

GTx's new medical chief to lead Acapodene commercialization  -  Apr 5, 2007
Memphis Business Journal,...and he will provide outstanding medical leadership as we execute our commercialization plans for Acapodene and Ostarine," said Mitchell S. Steiner,

GTx, Inc. Announces First Quarter 2007 Financial Results ...  -  Apr 20, 2007
PharmaLive.com (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM),

GTx, Inc. Announces First Quarter 2007 Financial Results ...  -  Apr 20, 2007
Business Wire (press release),GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE®. GTx also is developing Ostarine™, a first-in-class

Market Report -- In Play (GTXI)  -  Apr 18, 2007
MSN MoneyGTX Analyst meeting confirms Acapodene Phase III timelines - Lazard Lazard notes that comprehensive registration strategy for Acapodene and Ostarine

GTx hires to prep for market  -  Apr 10, 2007
commercialappeal.com (subscription),Memphis pharmaceutical company GTx Inc. is in hiring mode as it prepares for a big push next year to bring its experimental prostate cancer drug, Acapodene,

GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory ...  -  Apr 10, 2007
Therapeutics Daily (subscription) (press release),Applications for ACAPODENE and as we advance Ostarine into late stage clinical trials," said Mitchell S. Steiner, MD, Chief Executive Officer of GTx.

Medtronic Buys Swinnea Road Distribution Center  -  Apr 4, 2007
Memphis Daily News,...medical leadership as we execute our commercialization plans for Acapodene and Ostarine," said Dr. Mitchell S. Steiner, GTx CEO, in a statement.

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.